UNSPSC 51435002: Sodium chloride/verapamil

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV200. This VA Drug Class (CV200) classifies this compound as belonging to the group CALCIUM CHANNEL BLOCKERS.

UNSPSC 51435002 Sodium chloride/verapamil is a Commodity code under which state and local governments procure advanced life support and emergency-response medications, along with generic pharmaceuticals and over-the-counter products for health system distribution. The recent solicitation activity shows purchasing bodies acquiring specific injectable medications — epinephrine, adenosine, diltiazem, and labetalol — in unit quantities ranging from hundreds to low thousands, with firm pricing that includes shipping, expiration-date warranties of nine months or longer, and delivery timelines of ten days or less. State health agencies and municipal fire-rescue departments drive demand; the code also captures broader multi-state cooperative purchasing for generic pharmaceuticals supplied through established pharmaceutical wholesalers. Issuing bodies include municipal purchasing departments (City of Tampa), state health commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). Small local business enterprise set-asides and accessibility documentation requirements appear in active solicitations.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's sealed-bid procurement (IFB No. 26P00188, due April 8, 2026) for Advanced Life Support Medications specified four medication line items totaling approximately 3,550 units for Tampa Fire Rescue with an estimated contract value of $40,000, renewable for up to five additional periods and sheltered under a 5 percent SLBE bid discount. The Texas HHS Commission issued a Request for Information (RFI No. HHS0017013, due April 3, 2026) to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program, signaling upstream state-level strategic procurement planning. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with effective dates of July 1, 2026, contract terms of two years, and emphasis on cGMP and Drug Supply Chain Security Act compliance through three authorized wholesalers.